Revenues (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):


	Three Months Ended June 30, 2020														Three Months Ended June 30, 2019
	U.S.		Europe		Other Locations		Total		U.S.		Europe		Other Locations		Total
Product sales:
Atripla	$	95	$	5	$	3	$	103	$	122	$	26	$	4	$	152
Biktarvy	1,350		153		101		1,604		1,023		73		20		1,116
Complera/Eviplera	27		42		3		72		42		72		9		123
Descovy	337		46		34		417		246		69		43		358
Genvoya	646		109		61		816		733		177		70		980
Odefsey	273		98		11		382		266		111		10		387
Stribild	39		12		8		59		78		24		6		108
Truvada	370		6		11		387		657		41		20		718
Other HIV⁽¹⁾	11		1		16		28		9		1		5		15
Revenue share – Symtuza⁽²⁾	90		40		2		132		55		29		—		84
AmBisome	10		49		36		95		10		60		35		105
Ledipasvir/Sofosbuvir⁽³⁾	24		4		39		67		86		22		85		193
Letairis	80		—		—		80		204		—		—		204
Ranexa	1		—		—		1		19		—		—		19
Sofosbuvir/Velpatasvir⁽⁴⁾	165		57		113		335		219		156		118		493
Vemlidy	76		7		68		151		71		5		40		116
Viread	3		8		54		65		9		28		38		75
Vosevi	27		6		6		39		53		15		7		75
Yescarta	95		56		5		156		99		21		—		120
Zydelig	8		9		1		18		12		14		—		26
Other⁽⁵⁾	43		16		1		60		41		97		2		140
Total product sales	3,770		724		573		5,067		4,054		1,041		512		5,607
Royalty, contract and other revenues	14		62		—		76		19		58		1		78
Total revenues	$	3,784	$	786	$	573	$	5,143	$	4,073	$	1,099	$	513	$	5,685


	Six Months Ended June 30, 2020														Six Months Ended June 30, 2019
	U.S.		Europe		Other Locations		Total		U.S.		Europe		Other Locations		Total
Product sales:
Atripla	$	176	$	12	$	10	$	198	$	255	$	42	$	26	$	323
Biktarvy	2,762		334		201		3,297		1,762		121		26		1,909
Complera/Eviplera	51		89		8		148		86		134		18		238
Descovy	700		107		68		875		479		137		84		700
Genvoya	1,258		260		122		1,640		1,461		370		164		1,995
Odefsey	542		225		24		791		548		217		19		784
Stribild	73		29		10		112		145		42		17		204
Truvada	753		14		26		793		1,208		74		42		1,324
Other HIV⁽¹⁾	14		3		19		36		20		2		10		32
Revenue share – Symtuza⁽²⁾	162		78		4		244		97		53		—		150
AmBisome	28		108		78		214		18		117		63		198
Ledipasvir/Sofosbuvir⁽³⁾	77		15		87		179		203		49		166		418
Letairis	163		—		—		163		401		—		—		401
Ranexa	9		—		—		9		174		—		—		174
Sofosbuvir/Velpatasvir⁽⁴⁾	476		179		244		899		449		310		225		984
Vemlidy	149		14		124		287		136		9		72		217
Viread	7		19		79		105		21		42		84		147
Vosevi	60		17		10		87		98		31		9		138
Yescarta	198		93		5		296		189		27		—		216
Zydelig	16		21		1		38		23		29		1		53
Other⁽⁵⁾	85		34		4		123		77		117		8		202
Total product sales	7,759		1,651		1,124		10,534		7,850		1,923		1,034		10,807
Royalty, contract and other revenues	31		110		16		157		41		114		4		159
Total revenues	$	7,790	$	1,761	$	1,140	$	10,691	$	7,891	$	2,037	$	1,038	$	10,966


____________________
(1)			Includes Emtriva and Tybost.
(2)			Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC.
(3)			Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4)			Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5)			Includes Cayston, Hepsera and Sovaldi.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2020		2019		2020		2019
AmerisourceBergen Corp.	21	%	20	%	21	%	20	%
Cardinal Health, Inc.	23	%	21	%	23	%	21	%
McKesson Corp.	23	%	20	%	22	%	20	%